News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,713 Results
Type
Article (17861)
Company Profile (296)
Press Release (315556)
Section
Business (96288)
Career Advice (388)
Deals (19052)
Drug Delivery (36)
Drug Development (55110)
Employer Resources (39)
FDA (7530)
Job Trends (6932)
News (175921)
Policy (14990)
Tag
Academia (1218)
Alliances (26515)
Alzheimer's disease (879)
Approvals (7526)
Artificial intelligence (95)
Bankruptcy (166)
Best Places to Work (6060)
Biotechnology (243)
Breast cancer (143)
Cancer (1165)
Cardiovascular disease (87)
Career advice (332)
CAR-T (90)
Cell therapy (261)
Clinical research (44053)
Collaboration (444)
Compensation (183)
COVID-19 (1545)
C-suite (114)
Cystic fibrosis (76)
Data (1172)
Diabetes (112)
Diagnostics (2203)
Earnings (34531)
Events (55970)
Executive appointments (380)
FDA (8108)
Funding (433)
Gene editing (76)
Gene therapy (191)
GLP-1 (358)
Government (2424)
Healthcare (8910)
Infectious disease (1608)
Inflammatory bowel disease (102)
IPO (10281)
Job creations (1204)
Job search strategy (298)
Layoffs (213)
Legal (2429)
Lung cancer (175)
Manufacturing (115)
Medical device (4469)
Medtech (4470)
Mergers & acquisitions (9076)
Metabolic disorders (328)
Neuroscience (1205)
NextGen: Class of 2025 (3061)
Non-profit (1461)
Northern California (1385)
Obesity (176)
Opinion (110)
Parkinson's disease (95)
Patents (86)
People (29904)
Phase I (15158)
Phase II (20282)
Phase III (13355)
Pipeline (509)
Postmarket research (1054)
Preclinical (6376)
Radiopharmaceuticals (218)
Rare diseases (247)
Real estate (2157)
Regulatory (11197)
Research institute (1200)
Series A (78)
Southern California (1264)
Startups (2302)
United States (11755)
Vaccines (293)
Weight loss (102)
Date
Today (70)
Last 7 days (396)
Last 30 days (1627)
Last 365 days (23210)
2025 (2267)
2024 (23391)
2023 (25890)
2022 (32114)
2021 (34396)
2020 (30892)
2019 (21991)
2018 (16149)
2017 (16997)
2016 (15107)
2015 (18352)
2014 (13267)
2013 (9968)
2012 (10327)
2011 (10361)
2010 (9674)
Location
Africa (242)
Arizona (79)
Asia (20413)
Australia (3451)
California (3224)
Canada (1018)
China (276)
Colorado (126)
Connecticut (136)
Europe (42713)
Florida (402)
Georgia (99)
Illinois (242)
Indiana (113)
Maryland (578)
Massachusetts (2467)
Michigan (113)
Minnesota (135)
New Jersey (859)
New York (895)
North Carolina (594)
Northern California (1385)
Ohio (107)
Pennsylvania (643)
South America (325)
Southern California (1264)
Texas (406)
Washington State (308)
333,713 Results for "spr therapeutics llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
SPR Therapeutics has been honored as a Top Workplace for the third consecutive year by cleveland.com and The Plain Dealer Top Workplaces program.
June 23, 2024
·
4 min read
Press Releases
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
October 17, 2024
·
6 min read
BioMidwest
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
SPR Therapeutics announced the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System.
May 13, 2024
·
6 min read
Press Releases
Nicoya Launches Alto Automation Suite to Facilitate SPR Integration Into High-Throughput Biologics Discovery Workflows
January 23, 2025
·
2 min read
Press Releases
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
October 29, 2024
·
8 min read
Press Releases
SPR® Therapeutics Debuts New SPRINT® PNS Data for Low Back, Shoulder, Knee, and Headache at the 23rd Annual ASRA Pain Medicine Meeting
November 21, 2024
·
8 min read
Drug Development
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
October 2, 2024
·
6 min read
BioMidwest
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee PainPain Relief Resulted in Improved Objective Measure of Walking Ability at End of Treatment
SPR Therapeutics announced the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System.
May 14, 2024
·
6 min read
Drug Development
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study.
February 28, 2024
·
7 min read
BioMidwest
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
SPR Therapeutics announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility.
February 1, 2024
·
6 min read
1 of 33,372
Next
